AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04414280 — intervention group
Intervention type: DEVICE
Intervention: Tandem Control-IQ
Description: The Tandem t:slim X2 Control-IQ consists of the Tandem t:slim X2 insulin pump with Control-IQ technology, and integrates with the Dexcom G6 CGM-device via Bluetooth. Blood glucose readings for calibration are not required. The Tandem t:slim X2 Control-IQ automatically adjusts basal insulin based on CGM readings to reach a glucose target range between of 112-160 mg/dL. Patients still need to enter their carbohydrate intake and administer meal-time boluses, but the system automatically increases the basal insulin dose or gives automated correction boluses in case of high blood glucose levels. The technology offers optional settings for sleep and exercise, with different glucose targets in order to match the insulin need during these activities. New versions of the pump software can be downloaded and installed remotely via the user's own computer.
Study NCT01872910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01872910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023703
Description: Administered orally
Study NCT01872910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study NCT01282801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride
Description: 150 mg Extended-Release Capsule
Study NCT01282801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® XR
Description: 150 mg Extended-Release Capsule
Study NCT04072341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis Period (Green Propolis 250mg/day)
Description: Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
Study NCT04072341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Period
Description: In the control period they will only follow standard treatment for their comorbidities.
Study NCT00100932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 28 Day Cycle
Description: E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
Study NCT00100932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 21 Day Cycle
Description: E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
Study NCT01602757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera
Description: Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3.
Study NCT01576367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT03354650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood culture
Description: blood culture to determine causative organisms of neonatal sepsis
Study NCT00595270 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IC51
Study NCT00633919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SLITone(TM) Dermatophagoides mix
Description: Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
Study NCT00633919 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual immunotherapy once daily for 2 years
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol inhaler
Description: 200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol inhaler
Description: 200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol inhaler
Description: 80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide/formoterol inhaler
Description: 80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: 5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone tablet
Description: 5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine tablet
Description: 5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desloratadine tablet
Description: 5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
Study NCT00633919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
Study NCT05157074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Drumming Music Therapy
Description: All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit.
Study NCT00297193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous haematopoietic stem cell transplant
Description: All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
Study NCT00954733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arterial blood draw
Description: One arterial blood draw
Study NCT01378910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unique
Description: Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
Study NCT01457105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)
Description: Metal stents placement in the main biliary duct during ERC
Study NCT02848716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery followed with chemoradiation
Description: Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy.
Study NCT02848716 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemoradiation
Description: patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy.
Study NCT02848716 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation
Study NCT04230655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low energy diet using meal replacements
Description: The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
Study NCT04230655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low energy diet using meal replacements
Description: The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
Study NCT04230655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-based group treatment
Description: All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
Study NCT04230655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based group treatment
Description: All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
Study NCT00981929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, losartan, caffeine
Description: 20 mg omeprazole 25 mg losartan 200 mg caffeine
Study NCT00981929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol, omeprazole, losartan, caffeine
Description: 50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
Study NCT04230655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Description: An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
Study NCT00535743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.
Study NCT00535743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
Study NCT00535743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Study NCT00535743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Study NCT03775226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChampioNIR® SFA Stent
Description: The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
Study NCT01350505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White light exposure
Description: \~200 lux of broad spectrum white light
Study NCT01350505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dim white light exposure
Description: \~28 lux of broad spectrum white light
Study NCT01350505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very dim white light exposure
Description: \<0.5 lux of broad spectrum white light
Study NCT01350505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dim orange light exposure
Description: \~28 lux of orange light
Study NCT03528174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Control system (APC)
Description: This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.
Study NCT03528174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacific Diabetes Technologies CGM Insulin Infusion system
Description: An integrated combination CGM/insulin infusion system
Study NCT02263001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular therapy for treatment of musculoskeletal pain
Study NCT02263001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
Study NCT01295723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Whole Breast Radiation Therapy
Description: Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~* Single reference dose per fraction: 2.7 Gy (ICRU)~* Number of fractions: 15~* Number of fractions per week: 5~* Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~* Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy
Study NCT01295723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Electron Radiation Therapy
Description: Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
Study NCT01054573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 750 mg orally every 8 hours (q8h) for 12 weeks
Study NCT01054573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (Peg-IFN) alfa-2a
Description: 180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
Study NCT01054573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: 1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
Study NCT04310917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood lipoprotein (a) test
Description: research specific blood sample
Study NCT03040921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine transposition.
Description: Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
Study NCT04651400 — intervention group
Intervention type: DRUG
Intervention: Antithrombin III
Description: Antithrombin III
Study NCT03058237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen Placarbil SR
Description: One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
Study NCT03058237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen Placarbil MR Prototype A
Description: One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
Study NCT03058237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen Placarbil MR Prototype B
Description: One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
Study NCT03058237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen Placarbil IR
Description: One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
Study NCT00905814 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
Study NCT00905814 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-103736
Description: single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
Study NCT02654457 — intervention group
Intervention type: PROCEDURE
Intervention: Women with Breast Cancer
Description: IVD Study
Study NCT01183013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15 mg
Description: Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
Study NCT01183013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg
Description: Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
Study NCT04658823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOV-12020 (Palm tocotrienols complex)
Description: Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
Study NCT04658823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Softgel capsule containing soybean oil; 1 capsule twice daily
Study NCT04402164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst appliance
Description: telescopic appliance for mandibular advancement
Study NCT02283359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
Study NCT02283359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
Study NCT02335151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Apply desflurane as anesthetic
Study NCT02566798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extract of grape and olive
Description: Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7
Study NCT02566798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7
Study NCT02914314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: oral suspension.
Study NCT02413463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: augmented recession
Description: medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
Study NCT02413463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Faden
Description: medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
Study NCT02006875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.